The overarching goal of the HCCC Experimental Therapeutics (ET) program is to develop and test novel cancer therapeutics. To accomplish this, ET has three central research themes: 1) Therapeutic Targets and Lead Discovery, 2) Novel Drug Delivery Approaches and 3) Clinical Therapeutics. ET has 30 full members and 17 associate members. Members have appointments across 3 colleges (Medicine, Pharmacy and Liberal Arts and Sciences) and 11 departments. Many ET members contribute to more than one theme. Total peer- reviewed annual research funding to ET is $4.33 million ($2.44 from the NCI) with $10.44 million in funding for non-peer reviewed research projects. ET members are highly productive and collaborative. ET members have authored or co-authored 305 cancer-related publications since April 1, 2011 with 49% (n=148) addressing therapeutic targets and lead discovery, 14% (n=43) addressing novel drug delivery approaches and 36% (n=108) addressing clinical therapeutics. 19% (n=59) were intra-programmatic, 37% (n=113) inter- programmatic, and 30% (n=93) inter-institutional. 26 manuscripts were published in high impact journals (impact factor >10). In the Therapeutic Targets and Lead Discovery theme, groups of investigators collaborate based on experimental therapeutics geared towards specific pathways, as well as cancer types. In the Novel Drug Delivery Approaches theme, ET investigators are evaluating nanoparticles, aptamers and novel approaches to cancer immunotherapy for treating prostate cancer, lymphoma, melanoma and breast cancer. Investigators in the Clinical Therapeutics theme are exploring mechanisms of action of clinical therapeutics and participating in or leading 145 active clinical trials across a spectrum of cancer types as coordinated through the disease specific Multidisciplinary Oncology Groups (MOGs). As a program, an increasing focus of ET is to facilitate movement of promising molecularly-targeted therapeutic approaches through the developmental therapeutics pipeline.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-20
Application #
9914256
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
20
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Schoenfeld, Joshua D; Sibenaller, Zita A; Mapuskar, Kranti A et al. (2018) Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models. Redox Biol 14:417-422
Kelpsch, Daniel J; Tootle, Tina L (2018) Nuclear Actin: From Discovery to Function. Anat Rec (Hoboken) 301:1999-2013
Gupta, Gaurav; Kuppachi, Sarat; Kalil, Roberto S et al. (2018) Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant 18:245-252
Garje, Rohan; Chau, Justin J; Chung, Jina et al. (2018) Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. J Immunother 41:42-44
Ruiz Ciancio, Dario; Vargas, Mauricio R; Thiel, William H et al. (2018) Aptamers as Diagnostic Tools in Cancer. Pharmaceuticals (Basel) 11:
Triplette, Matthew; Crothers, Kristina; Mahale, Parag et al. (2018) Risk of lung cancer in lung transplant recipients in the United States. Am J Transplant :
Andrew, Megan; Kim, Yusung; Ginader, Timothy et al. (2018) Reduction of applicator displacement in MR/CT-guided cervical cancer HDR brachytherapy by the use of patient hover transport system. J Contemp Brachytherapy 10:85-90
Buchakjian, Marisa R; Ginader, Timothy; Tasche, Kendall K et al. (2018) Independent Predictors of Prognosis Based on Oral Cavity Squamous Cell Carcinoma Surgical Margins. Otolaryngol Head Neck Surg 159:675-682
Keck, Kendall J; Breheny, Patrick; Braun, Terry A et al. (2018) Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases. Surgery 163:232-239
Brandt, Kristin E; Falls, Kelly C; Schoenfeld, Joshua D et al. (2018) Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells. Redox Biol 14:82-87

Showing the most recent 10 out of 1080 publications